SAN DIEGO, March 25, 2020 /PRNewswire/ — Stratify Genomics Inc., makers of the Prompt Prostate Genetic Score (PGS) test for Prostate Cancer risk assessment, announced their support of doctors across the country in their unprecedented but necessary shift to telemedicine while at the same time continuing to care for their patients during the COVID-19 outbreak.
“During these challenging and unforeseen times, healthcare is rapidly changing, and we are doing our part to support these ever-evolving changes. It is imperative that we shift focus as a company to help healthcare providers identify and triage patients by evaluating the needs for prostate biopsies and appropriate PSA based screening strategies for all men over the age of 40,” said Gina Anderson, Vice President, Commercial Operations.
Using advanced genetics, a data set consisting of well over 100,000 patients, the Prompt PGS test can categorize a man’s risk of developing prostate cancer in their lifetime with a simple cheek swab. The test provides a genetic score with stable, objective and actionable information to health care providers to help determine PSA based screening frequency and decisions to biopsy.